Yale selected as one of 25 clinical trial sites for treatment of neurological diseases

Yale is one of only 25 sites selected by the National Institutes of Health for the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT).

Yale has been approved as a clinical site for the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). NeuroNEXT, funded by the National Institutes of Health’s (NIH) National Institute of Neurological Disorders and Stroke (NINDS), is the premier NIH network for neuroscience clinical trials and biomarker studies and aims to streamline Phase II clinical trials for brain disorders.

Building on an already highly innovative environment, this award also brings cutting edge therapies to our community,” said Kevin Sheth, associate professor of neurology and neurosurgery and principal investigator (PI) for the grant. Sheth worked alongside his co-PI, professor of neurology Serena Spudich and associate professor of neurology, and NeuroNEXT co-Investigator Richard Nowak.

This network conducts both biomarker validation and Phase 2 studies of treatments for neurological diseases in adults and children through partnerships with academia, private foundations, and industry.

In response to the grant, Yale formed INFINITY (Investigations For Improved Neurological Treatments at Yale), a neuroscience clinical trials center headquartered in the Department of Neurology at the Yale School of Medicine.


Share this with Facebook Share this with X Share this with LinkedIn Share this with Email Print this

Media Contact

Bill Hathaway: william.hathaway@yale.edu, 203-432-1322